The Procter Gamble Company

The Cleveland Clinic Foundation

Angela Jane Deutsch

Thomas Alfred Inglin

Diane Danheiser Powers

Kelly Lee Schmeichel

Craig Andrew Hawkins

Kurt Franklin Trombley

Jay Robert Morosey, Jr

Rosa Manuela Leon Alonso

Eduardo De Abreu Mangione

Stanley Leon Hazen

John August Wos

David Thomas Stanton

Jose Carlos Garcia-Garcia

Michael Reilly

George Franklin Gerberick

David Blair Cody

Jodie Michelle Reed

Isabelle LaFosse-Marin

Jodie Michele Reed

Isabelle La Fosse-Marin

Isabella La Fosse-Marin

The invention provides a method of inhibiting the conversion of carnitine to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual one or more compositions comprising a compound set forth in Formula (I): Wherein the compound is administered in an amount effective to inhibit conversion of carnitine to TMA in the individual.

Methods for inhibiting conversion of carnitine to trimethylamine (TMA)

The invention provides one or more methods of inhibiting the conversion of choline to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual one or more compositions comprising a compound set forth in Formula (I): wherein the compound is administered in an amount effective to inhibit formation of trimethylamine (TMA) from choline in the individual.

Methods for inhibiting conversion of choline to trimethylamine (TMA)

A portable blister card including a front side and a back side opposite the front side. The front side includes a face having a width, a right side edge, a left side edge, a top edge, and an outer periphery. In addition, the front side includes a first blister and a second blister extending outwardly at the face and a primary manufacturer indicia area comprising a manufacturer indicator visible on the front side. The first blister contains a first unit dose and the second blister contains a second unit dose, wherein the first and second unit doses are different. The back side includes regulatory information that remains on the back side when each unit dose is removed from each blister through the back side of the card.

Blister cards promoting intuitive dosing

A daily blister card housing a unit dose includes a back side and a front side opposite the back side. The front side includes a manufacturer indicator visible on the front side. A face has an outer periphery and a total planar area bounded by the outer periphery. One or more blisters extend outwardly at the face that contains at least three unit doses that are visible from outside the one or more blisters. Each of the one or more blisters includes a shoulder contacting a cavity backing surface and a projected cavity area bounded by the shoulder that is projected onto the cavity backing surface. A total projected cavity area of the one or more blisters is no more than about 45 percent of the total planar area bounded by the outer periphery.

A conveniently portable daily blister card including a front side and a back side opposite the front side. The front side includes a face having a width, a right side edge, a left side edge, a top edge, and an outer periphery. In addition, the front side includes at least three blisters extending outwardly at the face and a primary manufacturer indicia area. Each blister contains a unit dose. The back side includes regulatory information that remains on the back side when a unit dose is removed from a blister through the back side of the card.

A blister card with a back side and a front side opposite the back side. The front side has a plurality of blisters and each blister contains a unit dose and each unit dose contains an active. Each blister card contains from about 12 hours to about 24 hours of unit doses according to the dosage instructions. The actives can be the same or different.

A daily blister card housing a unit dose includes a back side and a front side opposite the back side. The front side includes a manufacturer indicator visible on the front side. A face has an outer periphery and a total planar area bounded by the outer periphery. One or more blisters extend outwardly at the face that contain at least three unit doses that are visible from outside the one or more blisters. Each of the one or more blisters includes a shoulder contacting a cavity backing surface and a projected cavity area bounded by the shoulder that is projected onto the cavity backing surface. A total projected cavity area of the one or more blisters is no more than about 45 percent of the total planar area bounded by the outer periphery.

Growing community of inventors

West Chester, OH, United States of America

Angela Jane Deutsch